ConnexMD, Inc. – FDA Warning Letter, Oct 16, 2007

An FDA inspection conducted on October 15-16, 2007, at EchoConnex Communicator in Seattle, Washington, identified significant violations regarding the firm's manufacturing of the EchoConnex Communicator software, a medical device. The inspection revealed that the devices are adulterated under section 501(h) of the Act because the manufacturing, packing, storage, or installation methods do not conform to the Current Good Manufacturing Practice (cGMP) requirements of the Quality System (QS) regulation (21 C.F.R. Part 820). Key deficiencies include the failure to establish procedures for quality audits (21 C.F.R. § 820.22), conduct management reviews (21 C.F.R. § 820.20(c)), implement corrective and preventive action (CAPA) procedures (21 C.F.R. § 820.100(a)), and establish complaint handling procedures (21 C.F.R. § 820.198(a)). Furthermore, the firm failed to maintain records of complaint investigations (21 C.F.R. § 820.198(e)(6)) and lacked Medical Device Reporting (MDR) procedures (21 C.F.R. § 803.17), leading to misbranding. The FDA requires prompt corrective actions, including investigating root causes and addressing underlying system problems, with a response due within 15 working days. Failure to comply may result in regulatory actions such as seizure, injunction, civil penalties, and impact federal contracts, premarket submissions, and export certificates.